Abstract
Autoantibodies directed against the skeletal muscle acetylcholine receptor (AChR) play a critical role in the pathogenesis of the autoimmune disease, myasthenia gravis (MG). The pathogenic importance of anti-AChR antibodies is substantiated clinically by the often dramatic clinical improvement that follows removal of circulating antibodies utilizing extracorporeal plasma exchange (PE). Unfortunately, the effects of PE are non-specific as immunoglobulins (IgG) and other plasma proteins are removed in addition to anti-AChR IgG. In this study, we have successfully incorporated the AChR protein purified from Torpedo californicus into a Nanodisc (ND) membrane scaffold protein/phospholipid structure. We go on to demonstrate the effectiveness of this ND-AChR complex, administered intravenously, in the in vivo down-modulation of anti-AChR antibodies and subsequent amelioration of clinical disease in the experimental murine model of MG. These results provide proof-of-principle for the in vivo antigen-specific reduction of pathogenic anti-AChR antibodies utilizing ND-AChR particles. Further development of this strategy may provide an effective, antigen-specific, and readily accessible acute therapy for exacerbating MG or myasthenic crisis.
References
Mar 1, 1978·Journal of Neuropathology and Experimental Neurology·K SahashiV A Lennon
Jan 1, 1980·The Journal of Experimental Medicine·P W Berman, J Patrick
Sep 1, 1993·Cellular Immunology·S K GregorianA Rostami
Feb 1, 1995·Neurology·D GrobS Nakayama
May 1, 1997·International Immunology·H Tang, H Braley-Mullen
Jan 1, 1997·Immunologic Research·A C HoedemaekersM H De Baets
Mar 15, 2000·Muscle & Nerve·J M Lindstrom
Sep 7, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·H C ChiuJ H Yeh
Jul 17, 2003·The Journal of Clinical Investigation·Florence JambouSylvia Cohen-Kaminsky
Sep 10, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·M A TarnopolskyJ Turnbull
Mar 18, 2004·Journal of the American Chemical Society·I G DenisovS G Sligar
Sep 2, 2004·The Journal of Experimental Biology·M L TierneyS M Howitt
Jan 18, 2005·Journal of Neuroimmunology·Loukia Psaridi-LinardakiSocrates J Tzartos
Jul 26, 2005·Journal of Immunological Methods·Chen-Yun GuoJing-Ming Yuan
Apr 20, 2006·Archives of Biochemistry and Biophysics·Timothy H BayburtStephen G Sligar
Apr 28, 2006·Acta Neurologica Scandinavica. Supplementum·A Vincent
Jul 26, 2006·Proceedings of the National Academy of Sciences of the United States of America·Thomas BoldogGerald L Hazelbauer
Feb 1, 2007·Biochemistry·Abhinav NathStephen G Sligar
Mar 31, 2007·The Journal of Biological Chemistry·Timothy H BayburtStephen G Sligar
Dec 28, 2007·Current Opinion in Biotechnology·Hans C Fischer, Warren C W Chan
May 27, 2008·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jian Rong ShengMatthew N Meriggioli
May 21, 2009·Biological Chemistry·Jonas Borch, Thomas Hamann
Oct 16, 2009·Journal of Virology·Palash BhattacharyaBellur S Prabhakar
Nov 6, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jie LuoJon Lindstrom
Citations
Jul 27, 2011·Journal of Immunological Methods·Lixi NiuZhuoyu Li
Apr 15, 2015·Advanced Drug Delivery Reviews·Ronnie H FangLiangfang Zhang
Jul 2, 2015·PloS One·Pie HudaLise Arleth
Feb 9, 2017·Chemical Reviews·Ilia G Denisov, Stephen G Sligar
Jun 6, 2017·FEBS Letters·John E RouckAditi Das
Aug 14, 2018·Carcinogenesis·Noa LaviGera Neufeld
Apr 11, 2020·Neuron·Md Mahfuzur RahmanRyan E Hibbs
Mar 7, 2021·Membranes·Ekaitz Errasti-MurugarrenManuel Palacín